Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 9:16 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 529–552 of 2,695 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Autologous hematopoietic stem cell transplantation Clear all
Completed Phase 2 Interventional Results available

Busulfan Plus Melphalan Conditioning Regimen for Lymphoid Malignancies or Multiple Myeloma

NCT00427765
View directory record Official record
Conditions
Multiple Myeloma, Lymphoma
Interventions
Busulfan, Melphalan
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 65 Years
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 19, 2012 · Synced Oct 15, 2026, 9:16 PM EDT
Active, not recruiting Phase 3 Interventional

NOVOCART 3D Treatment Following Microfracture Failure

NCT03219307
View directory record Official record
Conditions
Articular Cartilage Defect
Interventions
NOVOCART 3D
Combination Product
Lead sponsor
Aesculap Biologics, LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2029
U.S. locations
3
States / cities
Chicago, Illinois • Columbus, Ohio • North Logan, Utah
Source: ClinicalTrials.gov public record
Updated Mar 21, 2025 · Synced Oct 15, 2026, 9:16 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Yttrium-90-labeled Daclizumab With Chemotherapy and Stem Cell Transplant for Hodgkin's Lymphoma

NCT01468311
View directory record Official record
Conditions
Hodgkin Disease, Hodgkin Lymphoma
Interventions
Auto stem cell transplant, BEAM, 111In-daclizumab, 90Y-daclizumab
Procedure · Drug · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 99 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 6, 2021 · Synced Oct 15, 2026, 9:16 PM EDT
Terminated Phase 1Phase 2 Interventional

A Phase I/II Study of BI-505 in Conjunction With Autologous Stem Cell Transplant in Multiple Myeloma

NCT02756728
View directory record Official record
Conditions
Multiple Myeloma
Interventions
BI-505, High dose melphalan, Autologous stem cell transplantation
Biological · Other
Lead sponsor
BioInvent International AB
Industry
Eligibility
18 Years to 70 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 12, 2020 · Synced Oct 15, 2026, 9:16 PM EDT
Completed Phase 1 Interventional

Vaccination With Lethally Irradiated Glioma Cells Mixed With GM-K562 Cells in Patients Undergoing Craniotomy For Recurrent Tumor

NCT00694330
View directory record Official record
Conditions
Glioma
Interventions
GM-K562 Vaccination
Biological
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 22, 2017 · Synced Oct 15, 2026, 9:16 PM EDT
Terminated Not applicable Interventional

Effect of Sleep Quality on Hematopoietic Cell Transplant Patient Outcomes

NCT04271930
View directory record Official record
Conditions
Sleep, Multiple Myeloma
Interventions
Mindfulness Awareness Practices for Insomnia, Sleep Health Information
Behavioral
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 9, 2024 · Synced Oct 15, 2026, 9:16 PM EDT
Terminated Phase 1 Interventional

Study of Safety and Efficacy of Genome-edited Hematopoietic Stem and Progenitor Cells in Sickle Cell Disease (SCD)

NCT04443907
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
OTQ923
Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
2 Years to 40 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
3
States / cities
Chicago, Illinois • New York, New York • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 8, 2026 · Synced Oct 15, 2026, 9:16 PM EDT
Completed Phase 2 Interventional Results available

Carfilzomib, Lenalidomide, and Dexamethasone Before and After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma

NCT01816971
View directory record Official record
Conditions
Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
Interventions
dexamethasone, carfilzomib, lenalidomide, autologous hematopoietic stem cell transplantation, laboratory biomarker analysis
Drug · Procedure · Other
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2026
U.S. locations
4
States / cities
Chicago, Illinois • Boston, Massachusetts • St Louis, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Oct 15, 2026, 9:16 PM EDT
Not listed Phase 2 Interventional

High-Dose Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Lung Cancer

NCT00003284
View directory record Official record
Conditions
Lung Cancer
Interventions
filgrastim, carboplatin, etoposide, ifosfamide, paclitaxel, peripheral blood stem cell transplantation, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Herbert Irving Comprehensive Cancer Center
Other
Eligibility
Not listed
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 6, 2014 · Synced Oct 15, 2026, 9:16 PM EDT
Active, not recruiting Phase 1 Interventional Results available

Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma

NCT03696784
View directory record Official record
Conditions
Lymphoma, Lymphoma, B-Cell, Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases
Interventions
iC9-CAR19 T cells, Bendamustine, Fludarabine, AP1903, Cyclophosphamide
Biological · Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2040
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 15, 2026, 9:16 PM EDT
Completed Phase 2 Interventional Results available

Randomized Double-Blind Phase 2 Efficacy and Safety of Autologous HB-MSCs vs Placebo for Treatment of Multiple Sclerosis

NCT05116540
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
HB-adMSCs, Placebo
Biological · Drug
Lead sponsor
Hope Biosciences Research Foundation
Industry
Eligibility
18 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Sugar Land, Texas
Source: ClinicalTrials.gov public record
Updated Sep 26, 2025 · Synced Oct 15, 2026, 9:16 PM EDT
Completed Phase 2 Interventional Results available

Autologous Stem Cell Transplant in Treating Patients With Progressive or Recurrent Hodgkin's Lymphoma

NCT00265889
View directory record Official record
Conditions
Lymphoma
Interventions
filgrastim, busulfan, cyclophosphamide, etoposide, melphalan, autologous-autologous tandem hematopoietic stem cell transplantation, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2010
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 20, 2013 · Synced Oct 15, 2026, 9:16 PM EDT
Not listed No phase listed Observational

Human Autograft Mesenchymal Stem Cell Mediated Stabilization of The Degenerative Lumbar Spine

NCT02529566
View directory record Official record
Conditions
Lumbar Degenerative Disc Disease, Lower Back Pain, Chronic Lower Back Pain
Interventions
Not listed
Lead sponsor
The Foundation for Spinal Research, Education and Humanitarian Care, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Odessa, Florida
Source: ClinicalTrials.gov public record
Updated Feb 15, 2017 · Synced Oct 15, 2026, 9:16 PM EDT
Not listed Phase 2 Interventional

Ovarian Dendritic Cell Vaccine Trial

NCT00703105
View directory record Official record
Conditions
Ovarian Cancer
Interventions
DC vaccination
Biological
Lead sponsor
Loyola University
Other
Eligibility
18 Years and older · Female only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2021
U.S. locations
1
States / cities
Maywood, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 26, 2021 · Synced Oct 15, 2026, 9:16 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Trima Non-DEHP Leukoreduced Red Blood Cell In Vivo Recovery Study

NCT06602804
View directory record Official record
Conditions
Device Validation of In-vivo Performance
Interventions
Trima Accel Auto RBC Collection
Device
Lead sponsor
Terumo BCT
Industry
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
2
States / cities
Cincinnati, Ohio • Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Oct 15, 2026, 9:16 PM EDT
Terminated Not applicable Interventional

Comparative Analysis of Virtuos and Autograft in Lumbar Fusion

NCT05614284
View directory record Official record
Conditions
Degenerative Disc Disease
Interventions
Virtuos
Device
Lead sponsor
Orthofix Inc.
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
3
States / cities
New Britain, Connecticut • Royal Oak, Michigan • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 28, 2025 · Synced Oct 15, 2026, 9:16 PM EDT
Completed Phase 1 Interventional

Vaccine Therapy in Treating Patients With Refractory Stage IV Cancer

NCT00057915
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
CEA peptide 1-6D
Biological
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 8, 2014 · Synced Oct 15, 2026, 9:16 PM EDT
Not listed Phase 1Phase 2 Interventional

Busulfan, Melphalan, Escalating Carfilzomib Conditioning Auto Stem Cell Transplantation for Multiple Myeloma (MM)

NCT03795597
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Carfilzomib, Busulfan IV, Melphalan IV
Drug
Lead sponsor
Loyola University
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Maywood, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 26, 2021 · Synced Oct 15, 2026, 9:16 PM EDT
Completed Phase 2 Interventional Results available

Phase II Feasibility Study of Dendritic Cell Vaccination for Newly Diagnosed Glioblastoma Multiforme

NCT00323115
View directory record Official record
Conditions
Glioblastoma Multiforme
Interventions
Autologous Dendritic Cell, Temozolomide, Radiotherapy, Dendritic Cell Vaccine
Biological · Drug · Procedure
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Oct 10, 2018 · Synced Oct 15, 2026, 9:16 PM EDT
Completed No phase listed Observational

Abdominal Obesity and Cardiovascular Risk Factors in Women Who Survived Cancer or a Related Illness Following Total Body Irradiation and Stem Cell Transplant

NCT00510315
View directory record Official record
Conditions
Leukemia, Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma, Myelodysplastic Syndrome
Interventions
Questionnaires, Laboratory tests, Abdominal MRI
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 49 Years · Female only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 7, 2020 · Synced Oct 15, 2026, 9:16 PM EDT
Terminated Not applicable Interventional Results available

Use of Platelet Rich Plasma After Arthroscopic Debridement for Triangular Fibrocartilage Complex Tears

NCT03805698
View directory record Official record
Conditions
Arthroscopic Surgery, Triangular Fibrocartilage Complex Injury
Interventions
Platelet-rich Plasma (PRP), Standard Arthroscopic Debridement
Device · Other
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 6, 2022 · Synced Oct 15, 2026, 9:16 PM EDT
Recruiting Phase 1Phase 2 Interventional

Autologous Adipose Cells Therapy

NCT06869252
View directory record Official record
Conditions
Hair Loss/Baldness, Wrinkle Appearance, Volume, Fine Lines, Skin Elasticity, Hair Thinning, Skin Pigmentation, Skin Texture
Interventions
Autologous Adipose Cells Therapy
Biological
Lead sponsor
CERM INC.
Industry
Eligibility
21 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
2
States / cities
Lewes, Delaware • Newark, Delaware
Source: ClinicalTrials.gov public record
Updated May 31, 2025 · Synced Oct 15, 2026, 9:16 PM EDT
Not listed Phase 1 Interventional

Natural Killer Cell (CYNK-001) Infusions in Adults With Multiple Myeloma

NCT04309084
View directory record Official record
Conditions
Multiple Myeloma, Neoplasm, Plasma Cell, Neoplasms by Histologic Type, Neoplasms, Hemostatic Disorder, Vascular Diseases, Cardiovascular Diseases, Paraproteinemias, Blood Protein Disorders, Hematologic Diseases, Hemorrhagic Disorders, Lymphoproliferative Disorders, Immunoproliferative Disorders, Immune System Diseases, Antineoplastic Agents, Analgesics, Non-Narcotic, Analgesics, Sensory System Agents, Peripheral Nervous System Agents, Physiological Effects of Drugs
Interventions
CYNK-001
Biological
Lead sponsor
Celularity Incorporated
Industry
Eligibility
18 Years to 75 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
4
States / cities
Denver, Colorado • St Louis, Missouri • Buffalo, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 16, 2023 · Synced Oct 15, 2026, 9:16 PM EDT
Completed Phase 2 Interventional Results available

Use of Adult Autologous Stem Cells in Treating People Who Have Had a Heart Attack (The TIME Study)

NCT00684021
View directory record Official record
Conditions
Left Ventricular Dysfunction
Interventions
Adult stem cells, Placebo
Biological
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
21 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
5
States / cities
Gainesville, Florida • Minneapolis, Minnesota • Cleveland, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2015 · Synced Oct 15, 2026, 9:16 PM EDT